Vergleich

Human C5 Monoclonal Antibody Europäischer Partner

ArtNr YR0002-1mg
Hersteller Abclonal
Menge 1 mg
Quantity options 1 mg 20 mg 5 mg
Kategorie
Applikationen ELISA, FA, NT
Specific against other
Isotype IgG
Purity 89.8% Determined by SDS-PAGE
NCBI C5
Alias C5D,C5a,C5b,ECLZB,CPAMD4
Lieferbar
Manufacturer - Applications
ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways
Manufacturer - Category
Biosimilar
Manufacturer - Conjugate / Tag
<5% Determined by SECP
Storage Conditions
2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)
Background
Eculizumab, a recombinant humanized anti-C5 (the terminal Complement component 5) monoclonal antibody, selectively targets and inhibits the terminal portion of the complement cascade. Eculizumab is a first-in-class terminal complement inhibitor to treat paroxysmal nocturnal hemoglobinuria (PNH) with excessive destruction of red blood cells (hemolysis). Eculizumab is also the first agent to treat atypical hemolytic uremic syndrome (aHUS) with abnormal blood clots to form in small blood vessels throughout the body, leading to kidney failure, damage to other vital organs and premature death.The complement immune system destroys and removes foreign particles by the complement cascade triggered by foreign particles. The complement proteins activiated in order create holes or pores in the invading organisms, leading to their destruction. The complement immune system in patients can also destroy healthy cells and tissue, resulting in excessive destruction of red blood cells (hemolysis) or abnormal blood clots to form in small blood vessels throughout the body.When activated, C5 at a late stage in the complement cascade is involved in activating host cells, thereby attracting pro-inflammatory immune cells, while also destroying cells by triggering pore formation. Eculizumab specifically binds to C5 and inhibits the cleavage of C5 to C5a (a potent anaphylatoxin with prothrombotic and proinflammatory properties) and C5b by the C5 convertase, preventing the generation of the terminal complement complex C5b-9 (which also has prothrombotic and proinflammatory effects). Both C5a and C5b-9 cause the terminal complement-mediated events that are characteristic of PNH and aHUS. By doing so, the normal, disease-preventing functions of proximal complement system are largely preserved, while the properties of C5 that promote inflammation and cell destruction are impeded.
Manufacturer - Cross Reactivity
<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay
Immunogen
Human C5
Recommended Dilution
In Vivo Grade Recombinant Human IgG4-S228P Kappa Isotype Control Antibody
Route
1×PBS pH 7.0
Manufacturer - Research Area
Cancer immunology
Gene Symbol
C5

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 1 mg
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen